EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase I)Open Access · CC BY-NC-ND 4.0

Relative Bioavailability of Zongertinib, an Orally Administered HER2-Selective Tyrosine Kinase Inhibitor, under Fed and Fasted Conditions in Healthy Male Participants: Results from Two Randomized, Open-Label, Crossover Studies

Hélène Pereira, Stefan Wölke, Behbood Sadrolhefazi iD, Habib Esmaeili, Sven Wind, Guanfa Gan, Fabian Müller, David Minich, Kerstin Bader, Rolf Grempler iD, Yeuk Ki Law, Philipp M Roessner iD

Molecular Pharmaceutics · 2025

DOI: 10.1021/acs.molpharmaceut.5c00832 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Molecular Pharmaceutics, 2025. Verfasst von Hélène Pereira und 11 weiteren Autor:innen. Beteiligte Einrichtung: VennLife Sciences, Lage Mosten 29, 4822 NK Breda, The Netherlands. Hauptthemen laut MEDLINE: Protein Kinase Inhibitors, Erb-b2 Receptor Tyrosine Kinases, Pyridines. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Boehringer Ingelheim.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Human epidermal growth factor receptor 2 (HER2), also known as ErbB2, is mutated in various solid tumors. Zongertinib (BI 1810631) is a novel, orally administered, HER2-specific tyrosine kinase inhibitor that spares the epidermal growth factor receptor (EGFR), limiting EGFR-related adverse events. Zongertinib has recently received accelerated approval in the United States and China for patients with advanced, previously treated, HER2 mutant NSCLC. Two Phase I open-label crossover studies evaluated the effect of a high-fat, high-calorie meal on zongertinib bioavailability at two doses: 30 mg (NCT05380947) and 240 mg (NCT06075277). Healthy male participants were randomized to treatment sequences in which they received single doses of zongertinib (spray-dried dispersion formulations) under fed and fasted conditions. The washout interval was ≥14 days. The primary end points were the area under the concentration-time curve of zongertinib in plasma over the time from 0 to the last quantifiable data point (AUC0-tz), and the maximum measured concentration of zongertinib in plasma (Cmax). In NCT05380947, 13 participants received 30 mg of zongertinib. The ratios of adjusted geometric means demonstrated lower AUC0-tz and Cmax, under fed (n = 9) versus fasted (n = 12) conditions (fed/fasted, % [90% CI]: AUC0-tz, 74.2% [67.6-81.6]; Cmax, 53.5% [40.5-70.8]). In NCT06075277, the ratios of adjusted geometric means for AUC0-tz and Cmax were ∼26% higher under fed versus fasted conditions (fed/fasted, % [90% CI]: AUC0-tz, 126.6% [112.1-143.1]; Cmax, 126.1% [106.3-149.6]). In both studies, median tmax was delayed (NCT05380947/NCT06075277) under fed (3/4 h) versus fasted (1.5/2 h) conditions. Zongertinib demonstrated good bioavailability in healthy participants. A small dose-dependent food effect was observed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein Kinase InhibitorsErb-b2 Receptor Tyrosine KinasesPyridinesHumansMaleCross-Over StudiesAdultBiological AvailabilityFastingAdministration, OralMiddle AgedHealthy VolunteersYoung AdultFood-Drug InteractionsArea Under CurveTyrosine Kinase Inhibitors

Stichwörter der Autor:innen

HER2food effectpharmacokineticstyrosine kinase inhibitorzongertinib

Substanzen

Protein Kinase InhibitorsErb-b2 Receptor Tyrosine KinasesPyridinesTyrosine Kinase InhibitorsERBB2 protein, human

Autor:innen und Institutionen

  • VennLife Sciences, Lage Mosten 29, 4822 NK Breda, The Netherlands.
  • Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88397 Biberach an der Riss, Germany.
  • Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877-0368, United States.
  • Staburo GmbH, Aschauer Straße 26a, 81549 Munich, Germany.
  • Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Fahrstrasse 17, 91054 Erlangen, Germany.
  • Boehringer Ingelheim Pharma GmbH & Co. KG, Binger Str. 173, 55216 Ingelheim am Rhein, Germany.

ORCID-Profile: Behbood Sadrolhefazi, Rolf Grempler, Philipp M Roessner

Förderung

  • Boehringer Ingelheim

Zitieren

APA

Pereira, H., Wölke, S., Sadrolhefazi, B., Esmaeili, H., Wind, S., Gan, G., Müller, F., Minich, D., Bader, K., Grempler, R., Law, Y. K., & Roessner, P. M. (2025). Relative Bioavailability of Zongertinib, an Orally Administered HER2-Selective Tyrosine Kinase Inhibitor, under Fed and Fasted Conditions in Healthy Male Participants: Results from Two Randomized, Open-Label, Crossover Studies. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c00832

Vancouver

Pereira H, Wölke S, Sadrolhefazi B, Esmaeili H, Wind S, Gan G, et al. Relative Bioavailability of Zongertinib, an Orally Administered HER2-Selective Tyrosine Kinase Inhibitor, under Fed and Fasted Conditions in Healthy Male Participants: Results from Two Randomized, Open-Label, Crossover Studies. Molecular Pharmaceutics. 2025. doi:10.1021/acs.molpharmaceut.5c00832

BibTeX
@article{Pereira2025,
  author = {Pereira, Hélène and Wölke, Stefan and Sadrolhefazi, Behbood and Esmaeili, Habib and Wind, Sven and Gan, Guanfa and Müller, Fabian and Minich, David and Bader, Kerstin and Grempler, Rolf and Law, Yeuk Ki and Roessner, Philipp M},
  title = {Relative Bioavailability of Zongertinib, an Orally Administered HER2-Selective Tyrosine Kinase Inhibitor, under Fed and Fasted Conditions in Healthy Male Participants: Results from Two Randomized, Open-Label, Crossover Studies},
  journal = {Molecular Pharmaceutics},
  year = {2025},
  doi = {10.1021/acs.molpharmaceut.5c00832}
}
Kostenlos starten →